 ATLANTA, July 26, 2021 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase or Company, a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced that, after a review of safety, tolerability and pharmacokinetic data from the Companys Phase 1 clinical trial of IkT-148009 in healthy volunteers, the United States Food and Drug Administration FDA has given the Company clearance to begin a Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinsons patients. The randomized Phase 1 study investigated the safety, tolerability and pharmacokinetics PK of IkT-148009 in healthy volunteers aged 45 to 70 years old, with the objective of evaluating the safety, tolerability and the PK profile of IkT-148009 in single and multiple ascending dose settings. 